Navigation Links
DH-2000-DUV with integrated shutter and external TTL control from Ocean Optics

ProductsDH-2000-DUV with integrated shutter and external TTL control from Ocean Optics
Company Ocean Optics
Item DH-2000-DUV with integrated shutter and external TTL control
Price $3,733.36
Description Identical to the DH-2000, except that it uses a deep-UV deuterium bulb, which provides a 190-1700 nm wavelength range and comes with a shutter (controlled via a TTL signal or switch up to 5 Hz)

The DH-2000 Deuterium Tungsten Halogen Light Source combines the continuous spectrum of deuterium and tungsten halogen light sources in a single optical path. The combined-spectrum light source produces a powerful, stable output from 215-200 nm. In addition, deep-UV versions of the light source are available, providing a 190-1700 nm wavelength range.

Options and Accessories
Integrated shutters are also available with the DH-2000 and can be driven either by a switch or by a TTL signal. Another option is to include a filter holder with the system, which accepts filters up to 4 mm in thickness and as large as 25-mm square or 20-mm round in diameter. All versions of the DH-2000 have an SMA 905 Connector for easy coupling to our spectrometers and accessories via optical fiber, and a safety shutter for blocking the light when the fiber is not attached.

All versions of the DH-2000 have a potentiometer on the back of the light source to balance the light level between the deuterium and tungsten halogen light sources. This potentiometer allows you to adjust the optical power of the tungsten halogen light from 10-100%.

  • Dimensions: 150 mm x 135 mm x 319 mm
  • Weight: 6 kg
  • Power consumption: 25 W (deuterium); 20 W (tungsten halogen)
  • Wavelength range: 190-400 nm (deep-UV deuterium bulb) • 215-2000 nm (standard deuterium and tungsten halogen bulbs)
  • Humidity: 5-95% without condensation at 40 C
  • Lamp current: Operating 85 V/0.3A
  • Lamp lifetime: 1,000 hours
  • Lamp voltage: Ignition 350 V/20
  • Current voltage drift: <0.01% per hour
  • Current voltage stability: <5 x 10-6 peak-to-peak (0.1-10.0 Hz)
  • Operating temperature: 5 C - 35 C
  • 5 C - 35 C 85-264 V 50/60 Hz
  • Radiation characteristic: Aperture 0.5 mm, numerical aperture 26 (13); focused Total power: 100 W
  • Power consumption: 190 W maximum
  • Warm-up time: 40 minutes (deuterium); • 20 minutes (tungsten halogen)
  • Markings: CE; VDI/VDE 0160; EN 61010
Info Ocean OpticsOcean Optics
830 Douglas Ave.
Dunedin, FL 34698 USA

Call Ocean Optics to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-727-475-1247
Customer Service: 727-733-2447
Fax Number: 727-733-3962
Web Site: http://www.oceanoptics.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. DH-2000-DUV with integrated shutter from Ocean Optics
2. DH-2000 with integrated shutter from Ocean Optics
3. D-2000 with integrated shutter from Ocean Optics
4. D-2000-DUV with integrated shutter from Ocean Optics
5. Biomek NXP Multichannel Laboratory Automation Workstation (with integrated Gripper) from Beckman Coulter
6. Kit for BASE20/50 dual control unit KIT50EHTD from Wave Biotech now part of GE Healthcare
7. Explorer Software Suite. Complete software and PC for datalogging, programming, control and monitoring for Explorer SpeedVac System [please inquire for latest PC configuration] from Thermo Scientific
8. EDG-1 Western blot control from Exalpha Biologicals, Inc.
9. Pulsed Blue LED Excitation Source, 470 nm center wavelength from Ocean Optics
10. New Wave UP Ablation Chamber w/200 mJ Nd:YAG laser from Ocean Optics
11. LVF Kit: LVF-UV-HL, LVF-CUV-ADP, FHS-LVF, CVD-DIFFUSE from Ocean Optics
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Contains L-glutamine...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products:
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... New research from the University of Michigan Comprehensive ... protein that fuels an inflammatory pathway does not turn ... cancer stem cells. This provides a potential target for ... of the disease. The researchers identified a protein, ...
... glioblastoma cancers so difficult to treat is that malignant cells ... fibers and blood vessels to invade new locations. Now, researchers ... the cancer by using a film of nanofibers thinner than ... of invading new areas, the migrating cells latch onto the ...
... life on earth, is also its least explored environment. ... the ocean,s deep regions, exploiting the deep,s resources and ... for the planet at risk. Lisa Levin, a ... San Diego, believes the vital functions provided by the ...
Cached Biology News:New finding points to potential options for attacking stem cells in triple-negative breast cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4Scientists call for new stewardship of the deep ocean: Earth's last frontier 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 3
(Date:4/16/2015)... ROCKVILLE, Md. , April 16, 2015 /PRNewswire/ ... "RegeneRx") today announced its U.S. joint venture with ... conduct a phase 3 clinical trial for the ... dose-response, confirmatory trial for dry eye syndrome (DES) ... ReGenTree,s preservative-free eye drops, RGN-259/GBT201, this year.  Each ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... April 16, 2015 Avelas Biosciences, an ... cancer surgeries, announced today that it has initiated a ... AVB-620, in women with primary, non-recurrent breast cancer undergoing ... welcomed the addition of Steven Chen , M.D., ... open label, dose escalation study will enroll up to ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3